Royalty Pharma plc filings document the company’s biopharmaceutical royalty business, public equity structure, governance, financing activity, and material events. Form 8-K reports furnish quarterly and annual results, including Portfolio Receipts, Royalty Receipts, operating cash flow, guidance, dividends, and developments affecting royalty and funding arrangements.
Regulation FD and material-agreement disclosures describe royalty transactions, synthetic royalty funding, senior secured loan arrangements, and portfolio-related clinical or regulatory events. Other filings cover Class A ordinary shares listed on Nasdaq, senior note issuances and related guarantees, annual meeting matters, board and compensation governance, shareholder voting items, and changes involving directors or officers.
Royalty Pharma plc executive Marshall Urist, EVP of Research & Investments, reported an open-market sale of 13,684 Class A Ordinary Shares on May 14, 2026 at a weighted average price of $53.0647 per share. The trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2026.
Following the sale, Urist directly holds 31,881 Class A Ordinary Shares and indirectly holds 19,020 shares through an IRA. The sale price reflected multiple transactions within a range of $52.88 to $53.25 per share.
Royalty Pharma plc director Gregory Norden reported an open-market sale of Class A Ordinary Shares. On May 14, 2026, he sold 3,045 shares at $53.00 per share. After this transaction, he directly holds 191,803 Class A Ordinary Shares.
The filing notes the trade was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2026, indicating the sale timing was scheduled in advance rather than decided opportunistically.
Royalty Pharma plc filed a Form 144 reporting the proposed sale of 3,045 shares of Common Stock on 05/13/2026. The notice lists Merrill Lynch, 225 Liberty Street, Floor 37, New York as the broker and references the vesting of restricted stock unit awards granted under the issuer equity compensation plan.
Royalty Pharma plc reported a proposed sale under Form 144 for 13,684 shares. The filing lists related equity performance awards granted on 08/06/2025 (2,772 shares), 11/05/2025 (4,626 shares) and 02/11/2026 (6,286 shares).
The cover shows an aggregate value of $726,137.82 and the filing is dated 05/14/2026.
Royalty Pharma PLC disclosure: Capital International Investors reports beneficial ownership of 37,772,419 shares, representing 8.8% of the 428,418,612 shares believed to be outstanding. The filing is an Amendment No. 3 to a Schedule 13G/A and is signed on 05/13/2026.
The filing states CII has sole power to vote on 37,448,042 shares and sole dispositive power over 37,772,419 shares. The disclosure names the investment management entities that make up Capital International Investors.
Royalty Pharma plc director and CEO Pablo G. Legorreta received 143,821 Class A Ordinary Shares as an equity award. The shares were granted at $0.00 per share in connection with the settlement of Equity Performance Awards and are described as an exempt acquisition under Rule 16b-3. Following this grant, Legorreta directly holds 1,240,604 Class A Ordinary Shares. He also has indirect holdings through family members and related entities, including 1,040,410 shares held by the Legorreta Children 2002 Trust and 901,590 shares held by the GST-Exempt Legorreta 2012 Family Trust. The filing does not show any open-market purchases or sales, indicating a routine compensation-related share award rather than a discretionary trade.
Royalty Pharma plc EVP & CFO Terrance P. Coyne reported an exempt acquisition of Class A Ordinary Shares through an affiliated entity. On May 6, 2026, TPC RP EPA1 LLC, an entity associated with him, received 24,263 Class A Ordinary Shares at $0.00 per share in connection with the settlement of Equity Performance Awards pursuant to Rule 16b-3.
Following this award, TPC RP EPA1 LLC held 64,399 Class A Ordinary Shares indirectly. Additional holdings reported as of the same date include 1,500 shares held directly, 1,450 held indirectly by spouse, 23,270 held indirectly by IRA, and 24,170 held indirectly by spouse’s IRA.
Royalty Pharma plc executive Christopher Hite reported an exempt equity award rather than an open-market trade. On May 6, 2026, an entity associated with him, SCH Investment Partners LLC, acquired 24,263 Class A Ordinary Shares at $0.00 per share in connection with the settlement of Equity Performance Awards, treated as exempt under Rule 16b-3. Following this award, SCH Investment Partners LLC held 709,399 Class A Ordinary Shares indirectly. A separate entry shows 70,000 Class A Ordinary Shares held directly as of the same date, recorded as a holding entry without a reported purchase or sale.
Urist Marshall reported acquisition or exercise transactions in this Form 4 filing.
Royalty Pharma plc EVP Marshall Urist received a stock grant of 18,197 Class A Ordinary Shares on an exempt basis under Rule 16b-3, in connection with the settlement of Equity Performance Awards. The shares were awarded at no cash cost, increasing his direct holdings to 45,565 Class A Ordinary Shares, in addition to 19,020 shares held indirectly through an IRA.
Royalty Pharma plc reported higher first-quarter 2026 results, driven by growth in royalty income and strong cash generation. Total income and other revenues reached $630.6 million, up from $568.2 million a year earlier, and net income attributable to Royalty Pharma plc rose to $294.7 million from $239.3 million.
Basic and diluted earnings per Class A share were $0.67, compared with $0.55 in 2025. Operating cash flow was robust at $718.2 million, while the company recorded a $69.4 million non-cash impairment on its Tazverik royalty and recognized $122.3 million of share-based compensation following its 2025 internalization. Cash stood at $586.4 million and total debt principal at $9.18 billion as of March 31, 2026.